The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000411347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
15/12/2025
Date registered
Help: Date registered
2/04/2026
Date last updated
Help: Date last updated
2/10/2026
Date data sharing statement initially provided
Help: Data sharing statement date
2/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
The CHAMPION-MTX trial: Child Hood Arthritis Multi-omic Predictions Improving Outcomes Nationally-Methotrexate Taper eXperiment
Scientific title
A multicentre, open-label, parallel group, randomised controlled withdrawal trial comparing methotrexate discontinuation strategies in patients with minimally active juvenile idiopathic arthritis
Additional trial identifiers [1] 312820 0
Nil known
Universal Trial Number (UTN)
Trial acronym
CHAMPION-MTX
Related trial records
Participating in this study also involves participation in a biobank and registry study called the Australian Arthritis and Autoimmune Biobank Collaborative (A3BC; 2019/PID11585; 2019/ETH10386; ACTRN12621001564842). The A3BC works with the clinical trial team to provide supporting infrastructure for the capture of trial data and biospecimen collection/processing/storage services.

Health condition
Health condition(s) studied:
Juvenile idiopathic arthritis (JIA) 334906 0
Condition category
Condition code
Musculoskeletal 331453 331453 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 337154 337154 0 0
Autoimmune diseases

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Participants in CHAMPION-MTX are cared for by their usual paediatric rheumatologist, who will act as Principal Investigators or Associate Investigators in this project, with the support of a Research Assistant.

A run-in period of 3 months will be undertaken by all eligible patients.

If still eligible at the end of this run-in period, participants will then be randomised at a baseline visit in a 1:1 ratio to either immediate cessation (Arm 1 “STOP”), or gradual dose-reduction (Arm 2 “TAPER”) of methotrexate.
Arm 1 participants are involved in CHAMPION-MTX for 12 months.

The location of the intervention will be in the participant's home as per their usual treatment plans and according to their usual timing of their medication regimen. As an adherence measure, a compliance questionnaire will be collected (CQR5-Compliance Questionnaire for Rheumatology) at baseline and study endpoint. Adherence will also be assessed by the study team at each study visit.

In terms of support for this process, at the baseline (T0) treatment allocation visit, the research nurse/officer will guide the participants and/or caregivers through the “CHAMPION-MTX Disease Flare Intervention Support Plan”, which clearly provides contact details, on how to contact the research team and treating rheumatologist, as well as an action plan on how to manage their flares.

If participants and/or caregivers become upset or distressed as a result of their participation arrangements, the research nurse/officer will link the participant and/or caregivers to local counselling, psychological support, allied health, community services and/or other appropriate support.

If a flare occurs, depending on the severity, the intervention may be ceased and methotrexate restarted, or re-escalated to the previous dose to recapture disease remission.
Participants who flare will remain in the trial until they reach the study endpoint (i.e. 12 months from randomisation for Arm 1, and 18 months from randomisation for Arm 2), to monitor post-flare JIA disease re-capture rates.
Intervention code [1] 329362 0
Treatment: Drugs
Description of the comparator or control
For the purposes of this form, the comparator arm for this trial is the tapering arm (Arm2).
This gradual dose-reduction of Arm 2 will involve a 50% dose reduction of methotrexate over a 6-month period, before fully stopping this medication. Arm 2 participants are involved in CHAMPION-MTX for 18 months.

For patients in Arm 2, dose changes will be guided by a methotrexate down-titration protocol, which aims to approximately halve the methotrexate dose at treatment-allocation, and thereafter stop methotrexate 6 months later.
Dose reduction allowances have been made to account for the medication strengths available in Australia.

This comparator Arm 2 cohort follow the same visit schedule and monitoring for adherence, flares etc as Arm 1, except Arm2 remain in the trial for an additional 6 months due to the longer tapering strategy undertaken.
Control group
Active

Outcomes
Primary outcome [1] 339204 0
JIA flare rate
Timepoint [1] 339204 0
T-3 (start of run-in period); t0 (end of run-in), thereafter at 3,6,9,12,15,18 months until end of trial involvement and/or disease flare.
Secondary outcome [1] 439066 0
Overall JIA remission rate (as per cJADAS10)
Timepoint [1] 439066 0
Assessed every 3 months for duration of study period from T-3 period to the study endpoint or disease flare. The study endpoint is 12 months post-enrolment for Arm 1 (STOP Methotrexate at baseline visit) and 18 months post-enrolment for Arm2 (TAPER methotrexate at baseline visit)
Secondary outcome [2] 439067 0
Flare rate (as per Wallace Criteria)
Timepoint [2] 439067 0
Assessed every 3 months for duration of study period from baseline (i.e. end of run-in period) to the study endpoint. The study endpoint is 12 months post-enrolment for Arm 1 (STOP Methotrexate at baseline visit) and 18 months post-enrolment for Arm2 (TAPER methotrexate at baseline visit)
Secondary outcome [3] 439068 0
Time to flare (including both minor and major flares) Data stratified into major and minor flares.
Timepoint [3] 439068 0
Assessed every 3 months for duration of study period from baseline (i.e. end of run-in period) to the time to flare. The study endpoint is 12 months post-enrolment for Arm 1 (STOP Methotrexate at baseline visit) and 18 months post-enrolment for Arm2 (TAPER methotrexate at baseline visit)
Secondary outcome [4] 439069 0
Mean difference in Juvenile Arthritis Disease Activity Score (JADAS) scores
Timepoint [4] 439069 0
Assessed every 3 or 6 months for duration of study period from baseline T=0 (i.e. end of run-in period) to the study endpoint. The study endpoint is 12 months post-enrolment for Arm 1 (STOP Methotrexate at baseline visit) and 18 months post-enrolment for Arm2 (TAPER methotrexate at baseline visit)
Secondary outcome [5] 439070 0
Mean number of serious adverse events (SAEs), including uveitis
Timepoint [5] 439070 0
Assessed every 3 months for duration of study period from baseline (i.e. end of run-in period) to the study endpoint. Mean number calculated at end of study. The study endpoint is 12 months post-enrolment for Arm 1 (STOP Methotrexate at baseline visit) and 18 months post-enrolment for Arm2 (TAPER methotrexate at baseline visit)
Secondary outcome [6] 439071 0
Proportion who withdraw due to adverse events
Timepoint [6] 439071 0
End of Study analysis of all withdrawals
Secondary outcome [7] 439072 0
Mean change in physical function (multiple outcomes via differing instruments).
Timepoint [7] 439072 0
Assessed every 6 months for duration of study period from end of run-in, baseline to study endpoint. The study endpoint is 12 months post-enrolment for Arm 1 (STOP Methotrexate at baseline visit) and 18 months post-enrolment for Arm2 (TAPER methotrexate at baseline visit)
Secondary outcome [8] 439073 0
Mean change in health-care related quality of life (HRQoL)
Timepoint [8] 439073 0
Assessed every 6 months for duration of study period from end of run-in, baseline (T=0) to study endpoint. The study endpoint is 12 months post-enrolment for Arm 1 (STOP Methotrexate at baseline visit) and 18 months post-enrolment for Arm2 (TAPER methotrexate at baseline visit)
Secondary outcome [9] 439079 0
Direct and indirect medical care costs
Timepoint [9] 439079 0
Questionnaire/diary data collected 6-monthly throughout the study. Linkage data will be sought for up to 1 year preceding trial entry and 4 years after, depending on data linkage custodian approvals. This is expected to be data linkage to: Medicare Benefits Schedule, Pharmaceutical Benefits Scheme and hospitalisation and emergency admissions data.
Secondary outcome [10] 439080 0
Mean doses of non-DMARD therapy
Timepoint [10] 439080 0
Collected 3-monthly throughout the study (for the 12 months of study duration for ARM1 participants and 18 months for ARM2 participants)
Secondary outcome [11] 439081 0
Mean doses of Disease-Modifying Anti-Rheumatic Drug (DMARD/s)
Timepoint [11] 439081 0
Collected 3-monthly throughout the study; (for the 12 months of study duration for ARM1 participants and 18 months for ARM2 participants)
Secondary outcome [12] 439082 0
Tissue Analysis, including cell typing-Cytokines, Gene Expression, Proteomic profiling.
Timepoint [12] 439082 0
Variable timepoints based on specific analysis (to be described in substudy protocols once finalised). Biospecimen timepoints available are at Month 0,6 and 12 for ARM1 and Month 0, 6, 12 and 18 for ARM2.
Secondary outcome [13] 456370 0
Multiple cJADAS disease activity measures will be reported, including: cJADAS27
Timepoint [13] 456370 0
Assessed every 3 or 6 months for duration of study period from baseline T=0 (i.e. end of run-in period) to the study endpoint. (Study endpoints are at 12 months post-randomisation for ARM1 participants and 18 months for ARM2 participants)
Secondary outcome [14] 456371 0
Multiple JADAS disease activity measures will be reported, including: JADAS71
Timepoint [14] 456371 0
Assessed every 3 or 6 months for duration of study period from baseline T=0 (i.e. end of run-in period) to the study endpoint. (Study endpoints are at 12 months post-randomisation for ARM1 participants and 18 months for ARM2 participants)
Secondary outcome [15] 456372 0
Assessed use of NSAIDs
Timepoint [15] 456372 0
Collected 3-monthly throughout the study, until study endpoint. (Study endpoints are at 12 months post-randomisation for ARM1 participants and 18 months for ARM2 participants)
Secondary outcome [16] 456373 0
Assessed use of glucocorticoids (all types)
Timepoint [16] 456373 0
Collected 3-monthly throughout the study. (Study endpoints are at 12 months post-randomisation for ARM1 participants and 18 months for ARM2 participants)
Secondary outcome [17] 456374 0
Mean change in physical function (multiple outcomes via differing instruments). Recorded via instrument: JAMAR, JAMAR=The Juvenile Arthritis Multidimensional Assessment Report
Timepoint [17] 456374 0
Assessed every 6 months for duration of study period from end of run-in, baseline to study endpoint. (Study endpoints are at 12 months post-randomisation for ARM1 participants and 18 months for ARM2 participants)
Secondary outcome [18] 456375 0
Mean change in physical function (multiple outcomes via differing instruments). Recorded via instrument: PROMIS-25 (Patient Reported Outcome Measures Information System)
Timepoint [18] 456375 0
Assessed every 6 months for duration of study period from end of run-in, baseline to study endpoint. (Study endpoints are at 12 months post-randomisation for ARM1 participants and 18 months for ARM2 participants)

Eligibility
Key inclusion criteria
Inclusion Criteria
• Age of entry into study less than or equal to 21 years old
• Diagnosis, with onset before age of 16 years old, of polyarticular or oligoarticular course of JIA. This would include any of the following subtypes of JIA, as defined by 2001 ILAR classification criteria*
o Oligoarticular JIA, including both persistent and extended subcategories
o Seronegative polyarticular JIA, with negative RF
o Undifferentiated arthritis
• Current therapy with methotrexate (MTX) for at least 12 months prior to study enrolment
• Stable low or inactive disease for at least 12 months prior to study enrolment as determined by the treating clinician
• Clinically inactive disease (CID) or Low Disease activity (LDA) confirmed by cJADAS10 scoring at enrolment, and completion of the 3 months run-in period.
• Informed consent from the participant and/or legal guardian to participate in the activities of the study
*Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004 Feb;31(2):390–2.
Minimum age
0 Years
Maximum age
21 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Exclusion Criteria
• Diagnosis with any of the following forms of JIA, as defined by 2001 ILAR classification criteria:
o Seropositive polyarticular JIA, with positive RF
o Systemic JIA
o Psoriatic arthritis
o Enthesitis related arthritis

• Active uveitis, and/or receiving treatment for uveitis within the last 12 months
• Corticosteroid use within the last 12 months including oral, intra-articular, or intra-ocular or intravenous modes of delivery
• Patients who had a b/tsDMARD, or investigational new drug within three months prior to enrolment.
• Patients who are primarily on immunomodulating agents for other health conditions, for example for inflammatory bowel disease.
• Concurrent medical conditions that in the opinion of the treating paediatric rheumatologist are likely to impact the patient’s safety or interfere with the evaluation of the study outcome (e.g. short life expectancy or planned major surgery).
• Neurological and/or psychological illness or condition such as to interfere with the patient’s ability to understand the requirements of the study.
• Despite the use of translation and interpreting services, there is insufficient language understanding and communication skills to provide informed consent and/or understand and participate in study processes.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation will be concealed. Clinicians won't know which arm participants will be randomised to a priori, and participants agree to be randomised according to a computer-generated randomisation table held centrally by the senior statistician and data manager (concealed group allocation)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A central computer-generated randomisation table will be used for sequence generation.
Randomization will be in 1:1 ratio for each treatment group, stratified by: disease subtype (i.e. polyarticular or oligoarticular course), methotrexate administration route (i.e. subcutaneous or oral), ANA result (i.e. positive or negative) and HLA-B27 gene status (i.e. present or absent). Providers and patients will be unblinded to allocation. Randomization will take place at the end of the run-in period (T0) remotely using a web-based assignment within the Research Electronic Data Capture (REDCap), applying the criteria stated previously. Allowances for run-in failures and dropouts will be factored into the allocation table.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 4
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
The estimated sample size is 106 participants in total. The primary hypothesis of the CHAMPION-MTX trial is that flare rates will be higher in Arm 1 (“STOP”), compared to Arm 2 (“TAPER”), at 12 months from last dose of methotrexate. Sample sizes of 48 in Arm 1 and 48 in Arm 2 achieve 80% power to detect a clinically meaningful difference between the group proportions of 0.30. The proportion in Arm 1 (“STOP”) is assumed to be 0.55 under the null hypothesis and 0.55 under the alternative hypothesis. This estimate is derived from the only previous methotrexate discontinuation randomised controlled trial in JIA. (23) Thus, the proportion in Arm 2 (“TAPER”) is assumed to be 0.25. The test statistic used is the two-sided Fisher's Exact Test. The significance level of the test is 0.05. To account for a combined run in failure and dropout rate of 10%, a minimum of 53 participants will be recruited in each arm.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,WA,VIC
Recruitment hospital [1] 28969 0
Sydney Children's Hospital - Randwick
Recruitment hospital [2] 28970 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [3] 28971 0
The Royal Childrens Hospital - Parkville
Recruitment hospital [4] 28972 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [5] 28973 0
Perth Children's Hospital - Nedlands
Recruitment hospital [6] 28974 0
Womens and Childrens Hospital - North Adelaide
Recruitment hospital [7] 28975 0
Monash Children’s Hospital - Clayton
Recruitment postcode(s) [1] 45221 0
2031 - Randwick
Recruitment postcode(s) [2] 45222 0
2145 - Westmead
Recruitment postcode(s) [3] 45223 0
3052 - Parkville
Recruitment postcode(s) [4] 45224 0
4101 - South Brisbane
Recruitment postcode(s) [5] 45225 0
6009 - Nedlands
Recruitment postcode(s) [6] 45226 0
5006 - North Adelaide
Recruitment postcode(s) [7] 45227 0
3168 - Clayton

Funding & Sponsors
Funding source category [1] 317258 0
Government body
Name [1] 317258 0
Australian Government, Department of Health, National Health and Medical Research Council, Medical Research Future Fund (MRFF)
Country [1] 317258 0
Australia
Primary sponsor type
University
Name
University of Sydney
Address
Country
Australia
Secondary sponsor category [1] 319536 0
None
Name [1] 319536 0
Address [1] 319536 0
Country [1] 319536 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 315994 0
Northern Sydney Local Health District Human Research Ethics Committee
Ethics committee address [1] 315994 0
Ethics committee country [1] 315994 0
Australia
Date submitted for ethics approval [1] 315994 0
19/12/2025
Approval date [1] 315994 0
06/02/2026
Ethics approval number [1] 315994 0
2025/ETH02792

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 136446 0
Prof Lyn March
Address 136446 0
Department of Rheumatology, Level 7C, Acute Services Building, Royal North Shore Hospital, Reserve Rd, St Leonards NSW 2065
Country 136446 0
Australia
Phone 136446 0
+61 2 9463 1765
Fax 136446 0
Email 136446 0
Contact person for public queries
Name 136447 0
Lyn March
Address 136447 0
Department of Rheumatology, Level 7C, Acute Services Building, Royal North Shore Hospital, Reserve Rd, St Leonards NSW 2065
Country 136447 0
Australia
Phone 136447 0
+6129463 1765
Fax 136447 0
Email 136447 0
Contact person for scientific queries
Name 136448 0
Lyn March
Address 136448 0
Department of Rheumatology, Level 7C, Acute Services Building, Royal North Shore Hospital, Reserve Rd, St Leonards NSW 2065
Country 136448 0
Australia
Phone 136448 0
+6129463 1765
Fax 136448 0
Email 136448 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Deidentified data and samples are available to all bona fide researchers who wish to conduct research in the public interest relating to musculoskeletal and autoimmune conditions, in particular juvenile arthritis.
All approved researchers will undergo the same application and approval processes as described in the A3BC Access Policy and be approved by the Access Committee, comprising highly experienced researchers.


Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Participant consent is given for any type of analysis that is in the public interest relating to musculoskeletal and autoimmune conditions.
All analyses must be reviewed and approved by a human research ethics committee, the A3BC Consortium Committee and Access Committee prior to release of samples and/or data.


When can requests for individual participant data be made (start and end dates)?
From:
Data will be available immediately following publication.
No end date has been determined as the collected data will form part of the ongoing, open-access A3BC Biobank-Registry dataset.



To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Bona fide researchers can apply for sample and/or data access through a 5-step application process:
1. Registration of Approved Researchers
2. Preliminary (Pre-HREC) Application
3. HREC Application
4. Main (Post-HREC) Application
5. Material Transfer Agreement (MTA) and Access Fees

The full A3BC Access Policy can be found on the A3BC website (https://a3bc.org.au/applications-and-access/)


Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.